Fairmount Funds Management LLC
CIK 1802528 · last filed 2026-09-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SYRE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 400
WEST CONSHOHOCKEN, PA 19428
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apogee Therapeutics, Inc. (APGE) Delisted | Director | 0 | $135.07 | $0 | $0 | 2 | 2026-09-03 |
| SYRE | Director | 0 | $92.91 | $0 | -$1.60B | 3 | 2026-06-23 |
| JBIO | Director | — | $14.50 | — | $0 | 1 | 2026-06-11 |
| VRDN | Director | 5,090,928 | $23.34 | $118.82M | $279.99M | 6 | 2026-05-13 |
| COGT | Director | 5,503,418 | $30.91 | $170.11M | -$82.90M | 7 | 2026-01-22 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | 2,747,866 | $15.70 | $43.14M | $72.95M | 1 | 2025-12-08 |
| DNTH | Director | 62,146 | $79.33 | $4.93M | $0 | 2 | 2024-04-01 |
| Cogent Biosciences, Inc. (UMRX) Delisted | 10%+ Owner | 1,147,406 | — | — | $0 | 2 | 2020-07-13 |
Recent Filings · Page 3 of 3
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-02-16 | COGT | Grant (A) | +1,166,666 | $8.75M | EDGAR |
| 2024-01-24 | DNTH | Grant (A) | +2,503,002 | $30.04M | EDGAR |
| 2024-01-24 | VRDN | Buy (P) | +2,380,950 | $50.00M | EDGAR |
| 2023-11-28 | SYRE | Conv (C) | +20,612,880 | $0 | EDGAR |
| 2023-06-13 | COGT | Buy (P) | +800,000 | $9.60M | EDGAR |
| 2022-06-21 | COGT | Buy (P) | +1,200,000 | $9.90M | EDGAR |
| 2021-09-23 | VRDN | Buy (P) | +4,545,000 | $49.99M | EDGAR |
| 2020-07-13 | Cogent Biosciences, Inc. (UMRX) Delisted | Buy (P) | — | $0 | EDGAR |
| 2020-07-08 | Cogent Biosciences, Inc. (UMRX) Delisted | Other (J) | +6,235,903 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.